Economic analysis of microneedle technology: cost-effectiveness, manufacturing scalability, and commercialization...

Microneedle technology represents a promising advancement in transdermal drug delivery, offering painless administration, enhanced patient compliance, elimination of cold chain requirements, and self-administration capabilities. Despite extensive development with over 4,000 patents, commercial translation remains limited to 13 products, predominantly cosmetic applications. Economic evaluations demonstrate microneedle patches achieve cost-effectiveness at price points below $30 per dose. Operational savings range from $0.24-$0.61 per dose across vaccination scenarios (≥ 87% probability), driven primarily by labor costs, followed by wastage reduction and freight decreases. Australian analysis projects $108 million annual savings for influenza vaccination through complete substitution of conventional systems. Manufacturing economics reveal significant barriers, with production facility establishment requiring $5-20 million capital investment and clinical development costs ranging from $10-40 million. Administration costs represent 43-63% of total vaccination expenses versus 8-10% for cold chain, identifying labor efficiency as the primary economic driver. Self-administration requires ≥ 3% compliance increases to offset administration success reductions. Manufacturing costs range from $0.50-$5.00 per patch, depending on scale and polymer selection. Regulatory pathways remain incompletely defined, creating uncertainties that delay market entry and increase expenditures. Regulatory approval costs reach hundreds of thousands to millions of dollars, while no microneedle patches have received FDA approval. Microneedle market projections indicate 6.83-7.2% compound annual growth from 2025 through 2030, reaching $4.46 billion globally. This review synthesizes reports from cost-effectiveness studies, manufacturing economics, regulatory pathways, and market dynamics, providing quantitative cost-effectiveness thresholds, identifying economic barriers, and offering recommendations for technology development, regulatory optimization, and market positioning to facilitate the clinical application of microneedle products.